Prescrire’s ratings of new products and indications over the past 10 years |
|
2013 |
2014 |
2015 |
2016 |
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
|
BRAVO |
0 |
1 |
0 |
0 |
0 |
0 |
0 |
1 |
0 |
0 |
|
A REAL ADVANCE
|
0 |
2 |
3 |
1 |
1 |
2
|
1 |
2 |
3 |
0 |
|
OFFERS AN ADVANTAGE
|
6 |
5 |
5 |
5 |
9 |
11 |
10 |
6 |
14 |
11 |
|
POSSIBLY HELPFUL
|
12 |
15 |
15 |
9 |
18 |
22 |
13 |
18 |
19 |
23 |
|
NOTHING NEW
|
48 |
35 |
43 |
56 |
45 |
50 |
61 |
55 |
51 |
63 |
|
JUDGEMENT RESERVED
|
9 |
10 |
6 |
5 |
4 |
5
|
9 |
17 |
12 |
13 |
|
NOT ACCEPTABLE
|
15 |
19 |
15 |
16 |
15 |
9
|
14 |
10 |
9 |
14 |
TOTAL |
90 |
87 |
87 |
92 |
92 |
99 |
108 |
109 |
108 |
124 |
|
Therapeutic advances in 2022 compared with
the previous 9 years |
|
|
|
In summary: a disappointing year
2022 was a return to the bad old days for medicines in Europe. Therapeutic advances were few and far between. Most newly authorised products or indications offered no proven advantages over existing treatment options, or were excessively dangerous. And yet again, certain pharmaceutical companies gave too little consideration to the ease of use of their products, choosing to market them in pack sizes ill-suited to the doses to be administered.
©Prescrire 1 April 2023
Source: "Prescrire's ratings of new drugs in 2022: a brief review" Prescrire International 2023; 32 (247): 99-101. Free.
Enjoy full access to Prescrire International, and support independent information
|